Bluejay Diagnostics shares surge 20.05% premarket after all prefunded warrants from October 2025 private placement are fully exercised.

Bluejay Diagnostics surged 20.05% in premarket trading following its announcement that all prefunded warrants from its October 2025 private placement had been fully exercised by February 19, 2026. The company now has 972,000 shares outstanding, with approximately 1.5 million cash-exercisable warrants remaining (exercise price $7.00 or higher). The resolution of prefunded warrants—a potential dilution risk—likely boosted investor confidence, while the firm reminder about pre-split share counts in recent 13G filings provided clarity on ownership structure. The move follows a 1-for-4 reverse stock split on January 29, 2026, which reduced shares outstanding but was not the primary catalyst for the premarket rally.